Age-Related Macular Degeneration

Galaxy Ophthalmics is developing next generation therapeutics for wet Age-Related Macular Degeneration (AMD) in partnership with i2 Pharmaceuticals, Inc. Building on i2 Pharma’s experience and intellectual property estate surrounding RNA, Small Molecule, Antibody and Antibody-like technologies, Galaxy is driven to develop new therapies for Ophthalmic diseases, with an initial focus on AMD. Galaxy is committed to developing new chemical entities for novel AMD targets, with a goal of sustained therapeutic activity and reduced dosing. The therapeutics being developed by Galaxy for AMD enjoy freedom to operate in areas of therapy currently blocked by traditional RNA and antibody therapeutics.

What we do...

Galaxy Ophthalmics is developing technologies related to new therapies for Glaucoma, Age-Related Macular Degeneration and Diabetic Macular Edema.